
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.

Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.

The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.

Protocolised treatable trait-based asthma management was acceptable to patients not under the care of a severe asthma clinic, associated with significant clinical benefit, and a full trial appears feasible.